SCHEMBL2130528

SCHEMBL2130528

COc1ccc(NCc2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.60
▸ RAB9A P51151 5/20 0.60
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ NPC1 O15118 5/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ ABCB1 P08183 2/20 0.59
▸ MEN1 O00255 7/20 0.57
▸ KMT2A Q03164 7/20 0.57
▸ LMNA P02545 1/20 0.57
▸ AKR1C3 P42330 1/20 0.57
▸ AKR1C2 P52895 1/20 0.57
▸ CRHBP P24387 4/20 0.56
▸ CRHR2 Q13324 4/20 0.56
▸ POLB P06746 3/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ ABCC1 P33527 1/20 0.56
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474847 0.89 HTR6 (0.58) MAPTSMN1; SMN2NPC1MEN1KMT2A
SCHEMBL10509856 0.87 MEN1 (0.54) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL9682949 0.87 MAPT (0.67) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL30984081 0.86 MAPT (0.57) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL25968280 0.86 MAPT (0.57) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL14356251 0.86 MAPT (0.53) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL5579572 0.85 MAPT (0.56) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL17934213 0.85 SMN1; SMN2 (0.62) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL7318993 0.83 MAPT (0.68) MAPTRAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL1180504 0.83 MAPT (0.57) MAPTRAB9ASMN1; SMN2NPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443092-A1 BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS Pfizer Inc. (US) 2012-04-25 — — EP disclosed
WO-2010146488-A1 BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS PFIZER INC. (US) 2010-12-23 — — WO disclosed
EP-0151826-B1 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines JANSSEN PHARMACEUTICA N.V. (BE) 1993-03-31 — — EP disclosed
Send feedback